JP2024521706A5 - - Google Patents
Info
- Publication number
- JP2024521706A5 JP2024521706A5 JP2023571805A JP2023571805A JP2024521706A5 JP 2024521706 A5 JP2024521706 A5 JP 2024521706A5 JP 2023571805 A JP2023571805 A JP 2023571805A JP 2023571805 A JP2023571805 A JP 2023571805A JP 2024521706 A5 JP2024521706 A5 JP 2024521706A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- haloalkyl
- group
- heterocycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163191631P | 2021-05-21 | 2021-05-21 | |
| US63/191,631 | 2021-05-21 | ||
| PCT/US2022/030227 WO2022246177A1 (en) | 2021-05-21 | 2022-05-20 | Axl compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024521706A JP2024521706A (ja) | 2024-06-04 |
| JP2024521706A5 true JP2024521706A5 (enExample) | 2025-05-27 |
| JP7843299B2 JP7843299B2 (ja) | 2026-04-09 |
Family
ID=82115693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571805A Active JP7843299B2 (ja) | 2021-05-21 | 2022-05-20 | Ａｘｌ化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240246967A1 (enExample) |
| EP (1) | EP4341261A1 (enExample) |
| JP (1) | JP7843299B2 (enExample) |
| CN (1) | CN117295741A (enExample) |
| TW (1) | TW202313602A (enExample) |
| WO (1) | WO2022246177A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR129722A1 (es) | 2022-06-28 | 2024-09-18 | Arcus Biosciences Inc | Compuestos inhibidores de axl |
| EP4554680A1 (en) | 2022-07-15 | 2025-05-21 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| WO2024020034A1 (en) | 2022-07-20 | 2024-01-25 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| TW202421150A (zh) | 2022-09-14 | 2024-06-01 | 美商阿克思生物科學有限公司 | 艾魯美冷之分散體 |
| EP4602041A1 (en) | 2022-10-14 | 2025-08-20 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| EP4705292A1 (en) | 2023-05-05 | 2026-03-11 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2024243502A1 (en) | 2023-05-25 | 2024-11-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| CN121285743A (zh) | 2023-06-02 | 2026-01-06 | 艾库斯生物科学有限公司 | 用于预测癌症治疗功效的生物标志物 |
| WO2025054339A1 (en) | 2023-09-08 | 2025-03-13 | Arcus Biosciences, Inc. | Triazolopyridine compounds as inhibitors of kit |
| WO2025072330A1 (en) | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
| EP4788432A1 (en) | 2023-10-06 | 2026-08-12 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| US12384773B2 (en) | 2023-11-02 | 2025-08-12 | Arcus Biosciences, Inc. | Thiazole compounds and methods of use thereof |
| WO2025137370A1 (en) * | 2023-12-20 | 2025-06-26 | Arcus Biosciences, Inc. | Salt forms of an axl inhibitor |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7361764B2 (en) * | 2004-07-27 | 2008-04-22 | Sgx Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール，インク． | Ｇｉｔｒ結合分子およびその使用 |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| IN2015DN02826A (enExample) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| DK2510010T3 (en) | 2009-12-10 | 2015-12-14 | Hoffmann La Roche | Antibodies that bind to human CSF1R extracellular domain 4 and their use |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| RU2617971C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| EP3943154A1 (en) | 2010-05-04 | 2022-01-26 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| LT3399984T (lt) | 2016-01-08 | 2023-11-10 | Arcus Biosciences, Inc. | 5'-nukleotidazės, ekto moduliatoriai ir jų panaudojimas |
| WO2018067424A1 (en) | 2016-10-03 | 2018-04-12 | Arcus Biosciences, Inc. | Inhibitors of adenosine 5'-nucleotidase |
| CN110022881B (zh) | 2016-11-18 | 2023-05-02 | 艾库斯生物科学有限公司 | Cd73介导的免疫抑制的抑制剂 |
| MX389798B (es) | 2017-01-20 | 2025-03-20 | Arcus Biosciences Inc | Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer. |
| EP3618829B1 (en) | 2017-05-05 | 2023-06-07 | Arcus Biosciences, Inc. | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders |
| AU2019312296B2 (en) | 2018-07-27 | 2025-05-29 | Arcus Biosciences, Inc. | Pyridone A2R antagonists |
| ES3053198T3 (en) | 2018-08-27 | 2026-01-20 | Arcus Biosciences Inc | Cd73 inhibitors |
| EP3880685B1 (en) | 2018-11-16 | 2025-06-18 | Arcus Biosciences, Inc. | Inhibitors of arg1 and/or arg2 |
| TW202039483A (zh) | 2018-11-22 | 2020-11-01 | 英屬開曼群島商百濟神州有限公司 | 作為HPK1抑制劑的吡咯並[2,3-b]吡啶以及它們的用途 |
| AU2020288610A1 (en) | 2019-06-04 | 2022-01-27 | Arcus Biosciences, Inc. | 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds |
| TWI848141B (zh) | 2019-07-04 | 2024-07-11 | 英屬開曼群島商百濟神州有限公司 | 及其用途 |
| EP4069212A4 (en) | 2019-12-04 | 2024-03-06 | Arcus Biosciences, Inc. | INHIBITORS OF HIF-2ALPHA |
| CA3173831A1 (en) | 2020-03-19 | 2021-09-23 | Arcus Biosciences, Inc. | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha |
-
2022
- 2022-05-20 WO PCT/US2022/030227 patent/WO2022246177A1/en not_active Ceased
- 2022-05-20 TW TW111118926A patent/TW202313602A/zh unknown
- 2022-05-20 US US18/555,963 patent/US20240246967A1/en active Pending
- 2022-05-20 JP JP2023571805A patent/JP7843299B2/ja active Active
- 2022-05-20 EP EP22731889.6A patent/EP4341261A1/en active Pending
- 2022-05-20 CN CN202280034430.8A patent/CN117295741A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024521712A5 (enExample) | ||
| JP7203964B2 (ja) | 統合的ストレス経路のプロドラッグ調節剤 | |
| JP2022535120A5 (enExample) | ||
| TWI838350B (zh) | 抗癌劑 | |
| JP2016506916A5 (enExample) | ||
| RU2468021C2 (ru) | Гетероциклические соединения и их применение | |
| JP6440212B2 (ja) | メトホルミン及びジヒドロケルセチンを含む組み合わせ医薬、及びがんの治療のための使用 | |
| JP2021523112A5 (enExample) | ||
| CN105683201B (zh) | 新的含n‑杂环碳烯配体的金(iii)络合物、合成及其在癌症治疗和硫醇检测中的应用 | |
| JP2020510032A5 (enExample) | ||
| JP2018504418A5 (enExample) | ||
| JP2022520061A5 (enExample) | ||
| JP2022507065A5 (enExample) | ||
| RU2015141772A (ru) | Новые соединения и композиции для ингибирования fasn | |
| JP2025525364A5 (enExample) | ||
| JP2019515952A5 (enExample) | ||
| JP2012158602A5 (enExample) | ||
| JP2017517548A5 (enExample) | ||
| JP2024541969A5 (enExample) | ||
| JP2021524835A (ja) | Ａｘｌキナーゼ阻害剤およびその使用 | |
| JP6198286B2 (ja) | 癌の処置のためのイソフラボノイド化合物および方法 | |
| RU2017112048A (ru) | Синергистические комбинации ауристана | |
| JP2019529518A5 (enExample) | ||
| JP2018529780A5 (enExample) | ||
| JP2019526560A5 (enExample) |